BRAF inhibition sensitizes melanoma cells to α-amanitin via decreased RNA polymerase II assembly

Despite the great success of small molecule inhibitors in the treatment of patients with BRAF(V600E) mutated melanoma, the response to these drugs remains transient and patients eventually relapse within a few months, highlighting the need to develop novel combination therapies based on the understa...

Descripción completa

Detalles Bibliográficos
Autores principales: Frischknecht, Lukas, Britschgi, Christian, Galliker, Patricia, Christinat, Yann, Vichalkovski, Anton, Gstaiger, Matthias, Kovacs, Werner J., Krek, Wilhelm
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6533289/
https://www.ncbi.nlm.nih.gov/pubmed/31123282
http://dx.doi.org/10.1038/s41598-019-44112-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6533289/
https://www.ncbi.nlm.nih.gov/pubmed/31123282
http://dx.doi.org/10.1038/s41598-019-44112-7

Ejemplares similares